In a breakthrough innovation in nanomedicine, a team of researchers at Indian Institute of Technology Mandi has created nano-dimensional capsules which can both diagnose and treat tumours, reports India Today.
The detection part is done by using multi-modal imaging, and the treatment is carried out via targeted drugs transported by the capsules. This field of medical science is known as Theranostics, where one multifunctional agent can simultaneously conduct three tasks- diagnosis, treatment and monitoring.
Theranostics is by no means a magic bullet to treat cancer or other maladies; however, it does provide for much individualistic treatment, meaning that more efficacious treatment may be given on a person-to-person basis.
The team led by Dr Jaiswal have used the modern availability of nanomaterials to try and implement the idea of theranostics in real life. The nanocapsules developed by the team conduct the diagnosis via a technique called Surface-Enhanced Raman Spectroscopy.
The therapeutic part of the treatment is carried out by delivering the fluorescent cancer drug Doxorubicin at the site of the tumour.
However, before the technology can really become of practical use, a number of further issues such as those related to the toxicity for the human body from such treatment, need to be addressed.
Comments ↓
An Appeal...
Dear Reader,
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.